ABSTRACT
There have been substantial changes in notions of prevention and management of Candida infection syndromes seen in critical care settings. Prospective randomized trials have been reported in the area of prophylactic therapy, and, although controversial, have legitimized the expansion of prophylactic therapy. Similarly, considerable information has come from therapeutic trials of new agents including the first echinocandin, caspofungin and an expanded spectrum imidazole, voriconazole. The availability of imidazoles and echinocandins warrant close review of the utility, if any, of continued use of amphotericin B and its derivatives in Candida infection. This review will focus on these particular issues.
